Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02635724 · ClinicalTrials.gov registry record · Phase 3
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
A Phase 3 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 74
- Enrollment target
NCT02635724 is a Phase 3 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 74 participants.
The verdict
NCT02635724, a Phase 3 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications. All subjects will receive IV peramivir.
Interventions
- DRUG Peramivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02635724
The ClinicalTrials.gov registry entry for NCT02635724 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peramivir is the first listed.
NCT02635724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02635724 about?
NCT02635724 is a clinical study titled "Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza". This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications. A...
What is the current status of trial NCT02635724?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 74 participants. The study started on 2015-12. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02635724?
The interventions under investigation include: Peramivir (DRUG).
Who is sponsoring clinical trial NCT02635724?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.